TY - JOUR
T1 - Antibody-based therapies for idiopathic pulmonary fibrosis
AU - Sgalla, Giacomo
AU - Flore, Maria Chiara
AU - Siciliano, Matteo
AU - Richeldi, Luca
PY - 2020
Y1 - 2020
N2 - Introduction: Pirfenidone and nintedanib have been the first agents demonstrating to slow down the progressive functional decline in patients with Idiopathic Pulmonary Fibrosis (IPF). Antibody-based therapies with precise molecular targets have been largely investigated over the last decade in IPF as alternative or complementary treatments, in the hope to ameliorate the relentless fibrotic process of IPF. Areas covered: In this review, we summarize the available evidence on two groups of monoclonal antibodies tested in IPF: those directed against known fibrogenic factors and matrix components, and those developed to antagonize the inflammation and immunity pathways. While the latter have failed to demonstrate any clinical efficacy in IPF so far, the anti-CTGF pamrevlumab has been recently proved to be capable of slowing down functional decline as compared to placebo, prompting further investigation. Expert opinion: Despite most trials on antibody-based therapies in IPF provided so far unsatisfying results, the therapeutic development in this field should continue to be pursued to deliver a more personalized treatment approach in the future, which is not currently offered by available treatment options. A more careful trial designing and the use of valid predictive markers of response to treatment are required to enhance effectiveness of future trials.
AB - Introduction: Pirfenidone and nintedanib have been the first agents demonstrating to slow down the progressive functional decline in patients with Idiopathic Pulmonary Fibrosis (IPF). Antibody-based therapies with precise molecular targets have been largely investigated over the last decade in IPF as alternative or complementary treatments, in the hope to ameliorate the relentless fibrotic process of IPF. Areas covered: In this review, we summarize the available evidence on two groups of monoclonal antibodies tested in IPF: those directed against known fibrogenic factors and matrix components, and those developed to antagonize the inflammation and immunity pathways. While the latter have failed to demonstrate any clinical efficacy in IPF so far, the anti-CTGF pamrevlumab has been recently proved to be capable of slowing down functional decline as compared to placebo, prompting further investigation. Expert opinion: Despite most trials on antibody-based therapies in IPF provided so far unsatisfying results, the therapeutic development in this field should continue to be pursued to deliver a more personalized treatment approach in the future, which is not currently offered by available treatment options. A more careful trial designing and the use of valid predictive markers of response to treatment are required to enhance effectiveness of future trials.
KW - IPF treatment
KW - Idiopathic pulmonary fibrosis
KW - antibody-based therapy
KW - interstitial lung disease
KW - precision medicine
KW - randomized clinical trials
KW - IPF treatment
KW - Idiopathic pulmonary fibrosis
KW - antibody-based therapy
KW - interstitial lung disease
KW - precision medicine
KW - randomized clinical trials
UR - http://hdl.handle.net/10807/151241
U2 - 10.1080/14712598.2020.1735346
DO - 10.1080/14712598.2020.1735346
M3 - Editorial
SN - 1471-2598
VL - 20
SP - 779
EP - 786
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
ER -